Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology

Abstract:
- Most potent photodisinfection agent known today -

University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology

LONDON, UK and VANCOUVER, Canada | Posted on October 9th, 2007

UCL Business PLC, and Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced an important
advance in photo-disinfection technology used to kill staphylococci such as methicillin-resistant Staphylococcus aureus (MRSA). In a multi-year collaborative research effort, scientists developed a nanotechnology-based photosensitizer that dramatically enhanced antimicrobial lethality at very small unit doses. The results of the research were published in the Royal Society of Chemistry's Journal of Materials Chemistry, 2007, 17, 3739-3746 and, because of the importance of the advancement, this publication has been selected for inclusion in the Royal Society of Chemistry's journal Chemical Biology Research Articles.

"The new nanoparticle photosensitizer is the most potent light-activated
antimicrobial agent known to date," said Dr. Cale Street, Director of
Research, Ondine Biopharma. "By covalently attaching gold nanoclusters to an
existing photosensitizer, we were able to dramatically boost bacterial killing
efficacy. We can now use very low concentrations of photosensitizer to achieve
greater than 99.99% eradication of bacteria in seconds to minutes, improving
our ability to develop photodisinfection-based products for the clinical
treatment of infections in wounds, burns, and other conditions."

"This development is the culmination of an intensive, cross-functional
research effort to develop next-generation anti-MRSA photodisinfection
agents," said Professor Michael Wilson, Division of Microbial Diseases,
University College London. "As resistance to antibiotics continues to increase
in most of the major human pathogens, this powerful technology has great
potential in the struggle against the growing prevalence of hospital-acquired
infections."

Ondine Biopharma owns exclusive rights to worldwide patent applications
covering this photodisinfection technology. With widespread antimicrobial
indications including eradication of MRSA from the nose and other areas,
treatment of conditions such as periodontal diseases, otitis externa, nailbed
fungus and the disinfection of burns and wounds.

####

About CL Business PLC
UCL Business PLC (UCLB) is the organisation responsible for
commercializing research generated within University College London (UCL) and
associated organisations. It is primarily responsible for protecting
inventions and transacting commercial activity including options, licences and
collaborative commercial research associated with the University. UCLB also
has responsibility for creating and spinning-out companies from UCL. UCLB is
wholly-owned by UCL and operates as an independent company with its own Board
of Directors.

About Periowave(TM) and Photodisinfection

Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
photosensitive compounds to specifically target and destroy microbial
pathogens and reduce the symptoms of disease. The compounds are topically
applied and lasers of appropriate wavelength and intensity are used to
disinfect the treatment site. The Company's Periowave(TM) photodisinfection
system is currently approved in Canada for nasal eradication of pathogenic
bacteria such as MRSA and the oral treatment of periodontitis, gingivitis,
peri-implantitis, peri-mucositis, endodontics, and in the European Union for
nasal eradication of MRSA, adult periodontitis, endodontics and
peri-implantitis. The photodynamic disinfection technologies were developed by
Professor Michael Wilson and colleagues at the Eastman Dental Institute,
University College London, and licensed to Ondine by UCL Business PLC,
University College London. Full text of the research publication described
above can be found at J. Mater. Chem., 2007, 17, 3739-3746. Additional
information about Periowave(TM) is available at http://www.periowave.com .

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: http://www.ondinebiopharma.com

Forward-Looking Statements:

Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

For more information, please click here

Contacts:
Carolyn Cross
President and Chief Executive
Officer
Ondine Biopharma Corporation
(604) 669-0555


Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269


Irma Gomez-Dib
Media & Investors Relations
FD International
(212) 850-5761


Nominated Adviser
Neil Johnson/Ryan Gaffney
Canaccord Adams Ltd
+44(0)20 7050 6500

Copyright © CNW Group Ltd.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

Announcements

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Patents/IP/Tech Transfer/Licensing

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanoparticles cause cancer cells to self-destruct April 3rd, 2014

A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014

Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014

Research partnerships

University of Waterloo Visits China to Strengthen Bonds With Research Partners April 21st, 2014

Novel stapled peptide nanoparticle combination prevents RSV infection, study finds April 17th, 2014

Scientists Capture Ultrafast Snapshots of Light-Driven Superconductivity: X-rays reveal how rapidly vanishing 'charge stripes' may be behind laser-induced high-temperature superconductivity April 16th, 2014

Scalable CVD process for making 2-D molybdenum diselenide: Rice, NTU scientists unveil CVD production for coveted 2-D semiconductor April 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE